Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mas ...Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 26, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modif ...
March 25, 2024
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency ...Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
– As of December 31, 2023 , Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to f ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 17, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 8, 2024
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study result ...Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...